Multiple Sclerosis Gene-Edited Cell Lines for Drug Discovery

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system, affecting approximately 2.8 million people worldwide (WHO, 2023). The global prevalence has increased by 30% since 2013, with an estimated incidence of 2.1 per 100,000 person-years. MS is the leading cause of non-traumatic neurological disability in young adults, with onset typically between 20 and 40 years of age. The disease course varies: 85% of patients present with relapsing-remitting MS (RRMS), which often transitions to secondary progressive MS (SPMS) within 10-15 years. Primary progressive MS (PPMS) accounts for 10-15% of cases. The economic burden is substantial, with annual direct and indirect costs exceeding $85,000 per patient in high-income countries (NCI, 2023). Key risk factors include Epstein-Barr virus infection, vitamin D deficiency, smoking, and genetic susceptibility (HLA-DRB1*15:01 allele).

MS is an ideal disease for mechanistic studies due to its complex immunopathology involving both adaptive and innate immune systems, as well as neurodegeneration. The availability of well-characterized subtypes (RRMS, SPMS, PPMS) and public datasets (e.g., MSBase, International MS Genetics Consortium) facilitates translational research. Open questions include the triggers of autoimmune attack, mechanisms of remyelination failure, and the transition from relapsing to progressive disease. Gene-edited cell models enable precise dissection of these pathways at the molecular level.

The pathogenesis of MS involves a complex interplay between immune cells and CNS components. Key pathways include:

• • Autoimmune T cell activation: Autoreactive CD4+ T cells (Th1 and Th17) recognize myelin antigens (e.g., MBP, PLP, MOG) presented by HLA class II molecules on antigen-presenting cells. This leads to clonal expansion and migration across the blood-brain barrier.
• • Steps:

1. Peripheral activation of naive T cells by myelin peptides.

2. Upregulation of adhesion molecules (VLA-4, LFA-1) and chemokine receptors (CCR5, CXCR3).

3. Transmigration across the blood-brain barrier via interaction with ICAM-1 and VCAM-1.

4. Reactivation within the CNS by local antigen-presenting cells (microglia, perivascular macrophages).

5. Secretion of pro-inflammatory cytokines (IFN-gamma, IL-17, TNF-alpha) leading to demyelination and axonal damage.

• • B cell and antibody-mediated mechanisms: B cells contribute through antigen presentation, cytokine production (IL-6, GM-CSF), and autoantibody production against myelin components. Oligoclonal bands in CSF are a hallmark of MS.
• • Microglial activation and neurodegeneration: Activated microglia release reactive oxygen species, glutamate, and pro-inflammatory cytokines, contributing to oligodendrocyte death and axonal injury. Chronic microglial activation is associated with progressive disease.

While MS is not a monogenic disease, genome-wide association studies (GWAS) have identified over 200 risk loci. The strongest genetic association is with the HLA region, particularly HLA-DRB115:01. Other significant variants include:

Several signaling networks are dysregulated in MS:

• • JAK-STAT pathway: Activated by cytokines (IFN-gamma, IL-6, IL-17), leading to STAT1 and STAT3 phosphorylation and pro-inflammatory gene expression. JAK inhibitors (e.g., tofacitinib) are being explored therapeutically.
• • NF-kB pathway: Constitutive activation in microglia and astrocytes promotes expression of inflammatory mediators (TNF-alpha, IL-1beta, iNOS).
• • PI3K/AKT/mTOR pathway: Hyperactivation in T cells enhances proliferation and survival, contributing to autoimmune responses.
• • Wnt/beta-catenin pathway: Involved in oligodendrocyte differentiation and remyelination. Dysregulation may impair repair processes.
• • Notch signaling: Regulates T cell differentiation (Th1 vs. Th17) and oligodendrocyte maturation.

Commonly used cell lines for MS research include:

Organoid models, such as brain organoids derived from iPSCs, offer a more physiologically relevant 3D environment for studying cell-cell interactions in MS. They can be used to model demyelination and remyelination, but are more complex and less scalable than cell lines.

Animal models are essential for studying MS pathogenesis and testing therapies:

• • Experimental autoimmune encephalomyelitis (EAE): The most widely used model, induced by immunization with myelin antigens (MOG, PLP, MBP) or by adoptive transfer of encephalitogenic T cells. It recapitulates many features of RRMS, including inflammatory demyelination and paralysis.
• • Examples:
• • MOG35-55-induced EAE in C57BL/6 mice (chronic model)
• • PLP139-151-induced EAE in SJL/J mice (relapsing-remitting model)
• • Adoptive transfer EAE using 2D2 T cell receptor transgenic mice
• • Cuprizone model: A toxin-induced model of demyelination and remyelination. Cuprizone (a copper chelator) is fed to mice, causing oligodendrocyte death and demyelination, primarily in the corpus callosum. Upon withdrawal, remyelination occurs, allowing study of repair mechanisms.
• • Viral models: Theiler's murine encephalomyelitis virus (TMEV) infection induces a chronic demyelinating disease similar to progressive MS.

CRISPR-based gene editing enables the generation of isogenic cell lines with precise genetic modifications, providing powerful tools for MS research. Key examples include:

• • *HLA-DRB115:01 knock-in cell lines: Introduction of the major risk allele into antigen-presenting cells (e.g., THP-1, dendritic cell lines) to study altered antigen presentation and T cell activation.
• • IL2RA knockout cell lines: Disruption of the IL2RA gene in T cell lines (e.g., Jurkat) to investigate the role of IL-2 signaling in Treg function and autoimmunity.
• • TNFRSF1A knockout cell lines: Deletion of TNF receptor 1 in microglial cell lines (e.g., HMC3) to study TNF signaling in neuroinflammation.
• • MBP knockout oligodendrocyte lines**: Loss of myelin basic protein to model impaired myelination and assess compensatory mechanisms.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, isogenic systems for functional studies. These models are generated using CRISPR/Cas9 technology and validated by Sanger sequencing and functional assays, ensuring high quality and reliability.

Gene-edited cell lines are instrumental for validating the functional impact of MS risk variants. For example:

• • *HLA-DRB115:01 knock-in in antigen-presenting cells: Demonstrates increased presentation of myelin peptides, leading to enhanced T cell activation and proliferation. This confirms the causal role of this allele in MS susceptibility.
• • IL7R knockout in T cells: Shows reduced T cell survival and proliferation, confirming the role of IL-7 signaling in maintaining autoreactive T cell clones.
• • CLEC16A knockout in B cells**: Reveals impaired autophagy and mitochondrial dysfunction, linking this variant to altered B cell function in MS.

Isogenic cell line pairs (wild-type vs. gene-edited) enable high-throughput drug screening to identify compounds that modulate specific pathways. For example:

• • Screening for inhibitors of T cell activation: Using HLA-DRB1*15:01 knock-in antigen-presenting cells co-cultured with T cells, libraries of small molecules can be screened for those that block T cell proliferation or cytokine production.
• • Modeling resistance to therapies: Knockout of genes involved in drug metabolism or target pathways (e.g., sphingosine-1-phosphate receptor modulators) can help understand mechanisms of treatment resistance in MS.

CRISPR-based screens in relevant cell types can identify synthetic lethal interactions and novel biomarkers. For example:

• • Genome-wide CRISPR knockout screens in microglial cells: Identify genes that, when disrupted, either promote or protect against neuroinflammation. Hits can be validated as potential therapeutic targets or biomarkers.
• • CRISPR activation screens in oligodendrocyte precursor cells: Identify genes that enhance remyelination, providing candidates for regenerative therapies.